核糖核苷酸还原酶抑制剂治疗肿瘤的研究进展  

Advances of Ribonucleotide Reductase Inhibitors on Cancer

作　　者：王安鸽 武喆 王莉[1] 裘云庆[2] WANG An’ge;WU Zhe;WANG Li;QIU Yunqing(State Key Laboratory for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, Zhejiang University, Hangzhou 310000, China;State Key Laboratory for Diagnosis and Treatment of Infectious Disease, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang Provincial Key Laboratory for Drug Clinical Research and Evaluation, The First Affiliated Hospital, Zhejiang University, Hangzhou 310000, China)

机构地区：[1]浙江大学第一附属医院传染病诊断与治疗国家重点实验室,杭州310000 [2]浙江大学第一附属医院传染病诊断与治疗国家重点实验室,传染病诊断与治疗协同创新中心,浙江省药物临床研究与评价重点实验室,杭州310000

出　　处：《肿瘤防治研究》2019年第8期741-745,共5页Cancer Research on Prevention and Treatment

摘　　要：核糖核苷酸还原酶(RR)是生物细胞中唯一催化二磷酸核糖核苷酸还原为二磷酸脱氧核糖核苷酸(dNTPs)的酶,调节dNTPs含量,在DNA合成及细胞增殖中至关重要,其过表达与肿瘤的发生发展有着明确的联系。目前RR抑制剂已应用于临床治疗肿瘤,以RR及其亚单位为潜在靶点开发新型抗癌药物,可望为临床治疗肿瘤提供新的选择。本综述从RR的结构和功能、RR在癌症发展中的作用、RR抑制剂的应用及研究前景几方面进行探讨。Ribonucleotide reductase(RR) regulates dNTP production, catalyzing the reduction of ribonucleotide into deoxyribonucleotide diphosphate, which is essential in DNA synthesis and cell proliferation. RR overexpression is related with the tumorigenesis and tumor progression. At present, RR inhibitors have been used on clinical cancer treatment, and new anticancer drugs have been developed targeting RR and its subunits, which may provide new options for cancer therapy. This review discusses the structure and function of RR, the role of RR on cancer therapy, and future application of RR inhibitors.

关 键 词：核糖核苷酸还原酶 酶抑制剂 肿瘤 

分 类 号：R730.5[医药卫生—肿瘤]